SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus

Vaccine

Volumn 25, Issue 4, 2007, Pages 630-637

  Kitabatake, Masahiro ^a,b   Inoue, Shingo ^c   Yasui, Fumihiko ^a   Yokochi, Shoji ^a,d   Arai, Masaaki ^a,e   Morita, Kouichi ^c   Shida, Hisatoshi ^f   Kidokoro, Minoru ^g   Murai, Fukashi ^d   Le, Mai Quynh ^h   Mizuno, Kyosuke ⁱ   Matsushima, Kouji ^b   Kohara, Michinori ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d Post Genome Institute Co Ltd   (Japan)

^e MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^f HOKKAIDO UNIVERSITY   (Japan)

^g NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^h NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

ⁱ Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

LC16m8; Recombinant vaccinia virus; SARS coronavirus

Indexed keywords

LC 16M8; NEUTRALIZING ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; SPIKE PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; GENE EXPRESSION REGULATION, VIRAL; IMMUNIZATION; MEMBRANE GLYCOPROTEINS; NEUTRALIZATION TESTS; RABBITS; SARS VIRUS; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 33845291925     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.039     Document Type: Article

References (32)

1. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1967-1976
2. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1953-1966
3. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 9366 (2003) 1319-1325
4. Gallagher T.M., and Buchmeier M.J. Coronavirus spike proteins in viral entry and pathogenesis. Virology 279 2 (2001) 371-374
5. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 6965 (2003) 450-454
6. Spaan W., Cavanagh D., and Horzinek M.C. Coronaviruses: structure and genome expression. J Gen Virol 69 Pt. 12 (1988) 2939-2952
7. Nie Y., Wang G., Shi X., Zhang H., Qiu Y., He Z., et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 190 6 (2004) 1119-1126
8. Wang Y.D., Sin W.Y., Xu G.B., Yang H.H., Wong T.Y., Pang X.W., et al. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J Virol 78 11 (2004) 5612-5618
9. Normile D., and Enserink M. SARS in China. Tracking the roots of a killer. Science 301 5631 (2003) 297-299
10. Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 5748 (2005) 676-679
11. Lau S.K., Woo P.C., Li K.S., Huang Y., Tsoi H.W., Wong B.H., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 102 39 (2005) 14040-14045
12. Haagmans B.L., Kuiken T., Martina B.E., Fouchier R.A., Rimmelzwaan G.F., van Amerongen G., et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10 3 (2004) 290-293
13. Tang L., Zhu Q., Qin E., Yu M., Ding Z., Shi H., et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 23 6 (2004) 391-394
14. Takasuka N., Fujii H., Takahashi Y., Kasai M., Morikawa S., Itamura S., et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 16 10 (2004) 1423-1430
15. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 6982 (2004) 561-564
16. Kim T.W., Lee J.H., Hung C.F., Peng S., Roden R., Wang M.C., et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 78 9 (2004) 4638-4645
17. Gao W., Tamin A., Soloff A., D'Aiuto L., Nwanegbo E., Robbins P.D., et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362 9399 (2003) 1895-1896
18. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101 17 (2004) 6641-6646
19. Buchholz U.J., Bukreyev A., Yang L., Lamirande E.W., Murphy B.R., Subbarao K., et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101 26 (2004) 9804-9809
20. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93 21 (1996) 11341-11348
21. Sugimoto M., Yasuda A., Miki K., Morita M., Suzuki K., Uchida N., et al. Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister original (LO) strains. Microbiol Immunol 29 5 (1985) 421-428
22. Yamaguchi M., Kimura M., and Hirayama M. Report of the National Smallpox Vaccination Research Committee: study of side effects, complications and their treatments. Clin Virol 3 (1975) 269-278
23. Jin N.Y., Funahashi S., and Shida H. Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression. Arch Virol 138 3-4 (1994) 315-330
24. Funahashi S., Itamura S., Iinuma H., Nerome K., Sugimoto M., and Shida H. Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses. J Virol 65 10 (1991) 5584-5588
25. Hong T.C., Mai Q.L., Cuong D.V., Parida M., Minekawa H., Notomi T., et al. Development and evaluation of a novel loop-mediated isothermal amplification method for rapid detection of severe acute respiratory syndrome coronavirus. J Clin Microbiol 42 5 (2004) 1956-1961
26. Shida H., Tochikura T., Sato T., Konno T., Hirayoshi K., Seki M., et al. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. Embo J 6 11 (1987) 3379-3384
27. Keng C.T., Zhang A., Shen S., Lip K.M., Fielding B.C., Tan T.H., et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J Virol 79 6 (2005) 3289-3296
28. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 79 5 (2005) 2678-2688
29. Subbarao K., McAuliffe J., Vogel L., Fahle G., Fischer S., Tatti K., et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78 7 (2004) 3572-3577
30. Czub M., Weingartl H., Czub S., He R., and Cao J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23 17-18 (2005) 2273-2279
31. Olsen C.W., Corapi W.V., Ngichabe C.K., Baines J.D., and Scott F.W. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol 66 2 (1992) 956-965
32. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 9 9 (2003) 1131-1137